The Quince Health Policy Analysis and Evidence-based Public Health
Home
CME | Pubwise | The Quince | Undergrad Teaching | Publishing | Personal
Home
Up

 



The Quince ...

 Issue 58
The Commission for Health Care Audit and Inspection

Systematic review of cost effectiveness studies of telemedicine interventions

The Commission for Healthcare Audit and Inspection

The news that Dame Dierdre Hine, an old friend of Wales, has left the Commission for Health Improvement because it was moving in a different direction makes the development of the new Commission of particular interest

The Department of Health has produced a new policy document – The NHS Plan: next steps for investment, next steps for reform – packed with a raft of freshly minted ideas. Released in the shadow of chancellor Gordon Brown’s Budget, Next steps contains some radical proposals for further change.

In particular, it heralds a major re-organisation – some might even say a revolution – in healthcare regulation. Under the proposals, a new, more independent regulator called the Commission for Healthcare Audit and Inspection will take over the job of scrutinising the NHS from the Commission for Health Improvement and the Audit Commission, as well as taking on regulation of the private sector from the National Care Standards Commission. This will have a different organisation in Wales, the Care Standards in Wales group.

At the same time, a new Commission for Social Care Inspection will be fashioned out of the Social Services Inspectorate, the remains of NCSC, and some parts of the Audit Commission. While the shake-up comes very soon after the formation of CHI, which is only two years old, and NCSC only started operating last month – the logic of bringing healthcare regulation under one roof is pretty strong. But this is more than just a re-organisation – it also signals three major changes in the way the NHS will be regulated in future.

First, CHI has tried hard to build a collaborative relationship with NHS organisation – ‘we’re here to help’ has been the mantra. And while it may not have seemed so for those on the receiving end of a CHI review, the commission has largely lived up to its improvement ideals. That seems likely to change. CHAI is being badged by politicians as an inspectorate – tough, demanding and sceptical. It may be pushed into adopting a more punitive, sanctions-based approach than CHI has done.

CHAI is also to regulate both the NHS and the private sector – which will immediately prompt calls for a level playing field and common standards and methods across both areas. That presents problems, because CHI and NCSC have taken different approaches to regulation. CHI focuses on systems and processes for clinical governance, while NCSC standards are more about facilities and structures.

CHI was moving towards directly inspecting the quality of clinical care but it seems unlikely that CHAI will want to adopt wholesale the NCSC standards and use them in the NHS. Plus it will be difficult to write good standards that cover everything from a small private clinic to a major acute hospital.

Another difference is that CHI has few formal powers – it relies on the DoH to enforce its recommendations. In contrast, NCSC can fine or even close down private healthcare providers. CHAI will need to have a similar approach to standard-setting and enforcement across both sectors, or it will be accused of double standards.

We are also being told that CHAI will be more independent of both the DoH and the NHS than its predecessor bodies, because its board will not be appointed by the health secretary but by the NHS Appointments Commission. However if it is going to be independent, CHAI should be funded independently, either through government allocation, which is not controlled by the DoH, or through fees charged to the bodies it regulates. The latter approach is probably the best way to give CHAI autonomy.

CHAI will be a powerful regulator, and it could be argued that the new chief inspector of healthcare may end up wielding more power and influence in the NHS than the permanent secretary at the DoH. That makes CHAI’s accountability to Parliament and the NHS a crucial concern. Rather than its board simply being appointed, perhaps a model should be adopted in which different key groups – patients, professionals, NHS organisations, and managers – are formally represented.

All in all, the regulation proposals in Next steps seem to signal a real transfer of power from the DoH to CHAI, and a step towards the DoH disengaging from the day-to-day management of the NHS.

Ref (web)

Back to top


Systematic review of cost effectiveness studies of telemedicine interventions

A BMJ paper looked at this topic, which has been heavily encouraged in some medical circles, not least the manufacturers of equipment and purchasers keen to allow hospitals to undertake complex tasks under supervision.

They point up once again the great dearth of good cost-benefit studies available in research.

They systematically reviewed cost benefit studies of telemedicine by carrying out a systematic review of English language, peer reviewed journal articles. They searched for data in Medline, Embase, ISI citation indexes, and database of Telemedicine Information Exchange.

They found 55 of 612 identified articles that presented actual cost benefit data. They measured the scientific quality of reports assessed by use of an established instrument for adjudicating on the quality of economic analyses.

557 articles without cost data were categorised by topic. 55 articles with data were initially categorised by cost variables employed in the study. Only 24/55 (44%) studies met quality criteria justifying inclusion in a quality review, with 20/24 (83%) restricted to simple cost comparisons.

No study used cost utility analysis, the conventional means of establishing the “value for money” that a therapeutic intervention represents. Only 7/24 (29%) studies attempted to explore the level of utilisation that would be needed for telemedicine services to compare favourably with traditionally organised health care. None addressed this question in sufficient detail to adequately answer it. 15/24 (62.5%) of articles reviewed provided no details of sensitivity analysis, a method all economic analyses should incorporate.

Overall they conclude that there is no good evidence that telemedicine is a cost effective means of delivering health care. Their findings suggest that all new telemedicine enterprises should be put on hold unless there is a research element within the project looking at detailed cost-benefit analyses.

Ref: (web)

Back to top

 

Last updated:

Copyright 2003 | Norman Vetter


Send mail to njvetter@hotmail.com with questions or comments